North America Whole Exome Sequencing Market - Industry Trends and Forecast to 2029

North America Whole Exome Sequencing Market - Industry Trends and Forecast to 2029
North America whole exome sequencing market is projected to register a substantial CAGR of 22.0% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2023 to 2030.
Market Segmentation
North America Whole Exome Sequencing Market, By Component (Whole Exome Sequencing, Second-Generation Sequencing, and Third-Generation Sequencing), Product and Services (Systems, Kits and Services), Application (Diagnostics, Drug Discovery and Development, Personalized Medicine, Agriculture & Animal Research, and Others), End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Clinical Laboratories, and Others), Distribution Channel (Direct Trade, Retail Sales, and Others), Country (U.S., Canada, and Mexico) - Industry Trends and Forecast to 2030

Overview of North America Whole Exome Sequencing Market Dynamics
Driver
• Increase in the adoption of whole exome sequencing (WES)
Restraint
• Cyber security concerns in genomics
Opportunity
• Strategic initiative by the key market players

Market Players

Some of the key market players for the North America whole exome sequencing market are:
• Beckman Coulter, Inc.
• BIONEER CORPORATION
• Eurofins Scientific
• ExoDx (a part of Bio-Techne)
• FOUNDATION MEDICINE, INC. (A subsidiary of F. Hoffmann-La Roche Ltd)
• QIAGEN
• GeneFirst Limited
• Illumina, Inc.
• Meridian
• Merck KGaA
• SOPHiA GENETICS
• CD Genomics
• Twist Bioscience
• Thermo Fisher Scientific Inc.
• PerkinElmer Genomics (A Subsidiary of PerkinElmer Inc.)
• GeneDx, LLC
• Psomagen
• Integrated DNA Technologies, Inc.